Quick Order Cart

Cat. No. ARG27619

INO80C Knockout HAP1 Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Bone Marrow

  • Disease:

    Chronic myeloid leukemia

INO80C Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of near-haploid HAP1 chronic myeloid leukemia cells, offering disruption of the INO80C gene encoding a core subunit of the INO80 chromatin remodeling complex. This model targets nucleosome remodeling functions linked to DNA repair, transcription, and replication, with involvement of key factors such as RAD51, BRCA1, and the DNA damage marker ??H2AX. The polyclonal format enables pooled functional genomics screens, DNA damage response assays (e.g., comet assay, ??H2AX foci formation), and chromatin studies without clonal selection. Applications span cancer biology, genomic instability research, and drug sensitivity profiling in the context of leukemia. For more information, contact Ascent Research.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    HAP1

    Sex of Donor

    Male

    Age

    40 years

    Derived From Site

    Bone marrow

    Gene Name

    INO80C

    Gene Identifier

    NCBI Gene ID 125476

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    IMDM

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

INO80C Knockout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for constitutive disruption of the INO80C gene in the human near-haploid HAP1 cell line. This product provides a heterogeneous pool of gene-edited cells, enabling functional interrogation of INO80C without the need for single-cell cloning. The polyclonal format preserves biological variability while establishing a loss-of-function model, making it well-suited for pooled genetic screens and population-based functional assays.

HAP1 cells are derived from the KBM-7 chronic myeloid leukemia (CML) cell line, which was isolated from a patient in blast crisis. HAP1 exhibits a near-haploid karyotype, retaining a single copy of most chromosomes except for a disomic region of chromosome 15, which simplifies genetic knockout studies by eliminating confounding effects from a second functional allele. Despite its haploid nature, HAP1 maintains functional DNA repair, cell cycle control, and chromatin remodeling pathways, offering a streamlined genetic background to study genes involved in genome maintenance and leukemia biology.

INO80C is a core subunit of the INO80 ATP-dependent chromatin remodeling complex, which slides and evicts nucleosomes at gene promoters and DNA damage sites. Within the complex, INO80C interacts with INO80, RUVBL1, RUVBL2, ACTR5 (ARP5), IES2, and the histone variant H2A.Z to coordinate chromatin dynamics. The complex is recruited to double-strand breaks by ??H2AX, a modification catalyzed by ATM and ATR kinases, where it facilitates homology-directed repair by promoting nucleosome clearance and enabling the recruitment of RAD51 and BRCA1. INO80C also contributes to transcriptional regulation by modulating nucleosome positioning at target gene promoters, influenced by upstream signals from the cell cycle machinery and DNA damage checkpoints.

Disruption of INO80C in the HAP1 near-haploid context is expected to compromise INO80 complex activity, resulting in impaired DNA repair, altered gene expression programs, and increased sensitivity to genotoxic stress. This model is particularly valuable for dissecting the contributions of chromatin remodeling to CML and blast crisis progression, as well as to broader mechanisms of genomic instability in cancer. The combination of INO80C loss and the near-haploid background allows for clean phenotypic assessment of DNA damage signaling and repair pathway dependencies.

This polyclonal knockout cell population enables a diverse set of research applications, including genetic interaction screens to identify synthetic lethal partners, functional dissection of DNA damage response using ??H2AX foci formation, comet assays, and homology-directed repair reporter assays, and chromatin analyses via ChIP-qPCR to assess nucleosome occupancy. Transcriptional consequences can be explored by RNA-seq, while cell cycle effects are analyzed by flow cytometry. The cells are also applicable to drug sensitivity profiling and synthetic lethality screens in the context of CML. For additional details or purchasing information, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)